| Line Item | 2022-09-30 | Y/Y |
|---|---|---|
| R&D Expense | $37.9M | +15.0% |
| SG&A Expense | $13.1M | +44.9% |
| Operating Income | -$51.0M | -21.4% |
| Pre-tax Income | -$47.6M | -26.5% |
| Net Income | -$48.0M | -26.6% |
| Line Item | 2022-09-30 | Y/Y |
|---|---|---|
| Cash & Equivalents | $149.2M | -1.9% |
| Total Assets | $152.7M | -5.5% |
| Total Liabilities | $10.2M | -5.4% |
| Stockholders' Equity | $142.5M | -5.5% |
| Line Item | 2022-09-30 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$24.2M | +20.2% |
| Financing Cash Flow | $21.3M | -86.1% |